Sitagliptin/Telmisartan

西格列汀/替米沙坦

Report date: 2022/02/11 15:02:58

Base Information

Drug NameSitagliptin/Telmisartan
Drug Alias Name替米沙坦+西格列汀Telmisartan/SitagliptinTelmisartan+Sitagliptin替米沙坦/西格列汀西格列汀+替米沙坦 +[9] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsDipeptidyl peptidase IV inhibitors
TargetsAngiotensin II Receptor Type 1Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes MellitusHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Sitagliptin Phosphate MonohydrateTelmisartan
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesHyundai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHyundai Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes MellitusHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A